D-cycloserine Augmented CBT for Panic Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder

NCT00790868

Panic Disorder

COMPLETED PHASE2

D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia

NCT01102803

Phobic Disorders

COMPLETED PHASE3

Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

NCT00131339

Panic Disorder

COMPLETED NA

Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia

NCT00515879

Social Anxiety Disorder

COMPLETED PHASE3

Effect of D-cycloserine on Extinction of Fear Conditioning

NCT00352586

Fear

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Panic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

d-cycloserine

oral, capsule, 250 mg, once

Group Type EXPERIMENTAL

d-cycloserine

Intervention Type DRUG

cognitive-behaviour therapy

Intervention Type BEHAVIORAL

sugar pill

oral, capsule, once

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

cognitive-behaviour therapy

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

d-cycloserine

Intervention Type DRUG

placebo

Intervention Type DRUG

cognitive-behaviour therapy

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinical diagnosis of panic disorder
* at least moderate agoraphobic avoidance

Exclusion Criteria

* psychoactive medication last 6 weeks
* exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months
* female participant who is pregnant or breast-feeding
* lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder
* lifetime history of epilepsy or other significant disease or disorder

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No